Delving into the Latest Updates on Shenzhen Huayao Kangming Biopharmaceutical Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Shenzhen Huayao Kangming Biological Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in the research, development, production and sales of biopharmaceuticals. The company has a leading position in China's biopharmaceutical industry, and is committed to applying innovative technology to the development of biopharmaceutical products to meet the growing needs of the market and society.

Tags

Neoplasms

Endocrinology and Metabolic Disease

Urogenital Diseases

Oncolytic virus

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Oncolytic virus	2

Top 5 Target	Count

PSEN2(presenilin 2)	1

[Translation] An open-label, multicenter, dose-escalation Phase I clinical study to explore the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary efficacy of intratumoral injection of KM1 monotherapy in subjects with advanced malignant solid tumors whose disease has progressed after standard treatment or who are intolerant to chemotherapy or have no standard treatment

本研究是治疗晚期恶性实体瘤成人受试者的开放性、多中心、剂量递增的I期临床研究，目的是评价KM1单药瘤内注射在经标准治疗后疾病进展或对化疗不耐受或无标准治疗的晚期恶性实体瘤受试者中的安全性、耐受性、PK/PD及初步疗效，确定MTD及推荐的II期临床研究剂量（RP2D）。

[Translation]

This study is an open-label, multicenter, dose-escalation Phase I clinical study for the treatment of adult subjects with advanced malignant solid tumors. The purpose is to evaluate the safety, tolerability, PK/PD and preliminary efficacy of KM1 monotherapy injected intratumorally in subjects with advanced malignant solid tumors whose disease has progressed after standard treatment or who are intolerant to chemotherapy or have no standard treatment, and to determine the MTD and recommended Phase II clinical study dose (RP2D).

Start Date19 Apr 2023

Sponsor / Collaborator

Shenzhen Huayao Kangming Biopharmaceutical Co., Ltd.

NCT05684731 / RecruitingPhase 1IIT

A Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Tolerance and Preliminary Efficacy of KM1 Oncolytic Vaccinia Virus Injection Combined With Chemotherapy in Subjects With Recurrent or Refractory Ovarian Cancer

The purpose of this study is to determine if KM1 is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer, and explore the Recommend Phase 2 Dose (RP2D) of KM1 in the treatment of patients with recurrent or refractory ovarian cancer.

Start Date01 Feb 2023

Sponsor / Collaborator

Tongji Hospital Tongji Medical College of HUST

[+2]

100 Clinical Results associated with Shenzhen Huayao Kangming Biopharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shenzhen Huayao Kangming Biopharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Shenzhen Huayao Kangming Biopharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shenzhen Huayao Kangming Biopharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 16 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 1 Clinical

Login to view more data